The 12 New Drugs on the Horizon Presentation Titles for the AACR Annual Meeting 2026
Japan Approves Risovalisib For PIK3CA-Mutated Ovarian Clear Cell Carcinoma
Osimertinib Plus Chemotherapy Improves Outcomes in EGFR/TP53 mutant NSCLC: The TOP Study
Stephen V. Liu: Promising Results with Datopotamab Deruxtecan Combinations in NSCLC
Thymic Health And Immunotherapy Outcomes In Patients With Cancer
Yvonne Awards 2026
Opening of the 2026 Mark Symposium - The Mark Foundation for Cancer Research
Talha Badar: From Germline to Donor-Derived Mutations in MN
